DNAワクチンの北米市場予測

【英語タイトル】NORTH AMERICA DNA VACCINE MARKET FORECAST 2017-2025

Inkwood Researchが出版した調査資料(INKW711106)・商品コード:INKW711106
・発行会社(調査会社):Inkwood Research
・発行日:2017年10月
・ページ数:87
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:北米、米国
・産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD1,250 ⇒換算¥141,250見積依頼/購入/質問フォーム
Multi LicenseUSD1,500 ⇒換算¥169,500見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

KEY FINDINGSThe North America DNA vaccine market is predicted to flourish with a CAGR of 45.37% for the forecast period of 2017-2025, generating a market share of $9088 million by 2025.
MARKET INSIGHTS
The market is segmented according to the type of technology, applications, and DNA vaccine type. Opportunities like the chance to transform the healthcare landscape, along with the ease of storage and transport of these vaccines are profoundly shaping the market growth. The market is especially gaining popularity in the animal healthcare sector as the vaccines help in the insurance and counteractive action for many veterinary diseases. Also, the ongoing clinical trials for human DNA vaccine is considerably propelling the market ahead.

COMPETITIVE INSIGHTS
The leading companies in this market are Merck & Co, Madison Vaccines Incorporated (MVI), Glaxosmithkline Inc, Novartis Ag, Xenetic Biosciences Inc, Astellas Pharma Inc, Inovio Pharmaceuticals Inc and Vical Incorporated.

【レポートの目次】

1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
4. MARKET DETERMINANTS
4.1. DRIVERS
4.1.1. DNA VACCINES SHOWING GREAT PROMISE IN CHECKING THE RISING PREVALENCE OF DISEASE
4.1.2. THIRD GENERATION VACCINATION IS WITNESSING A SURGE IN INVESTMENT
4.1.3. INCREASING ADOPTION OF DNA VACCINES FOR ANIMAL HEALTHCARE
4.2. RESTRAINTS
4.2.1. LENGTHY REGULATORY PROCESS
4.2.2. POOR PATENT PROTECTION IN SOME COUNTRIES
4.3. OPPORTUNITIES
4.3.1. TRANSFORMING HEALTHCARE LANDSCAPE
4.3.2. NEW DEVELOPMENTS IN BIOTECHNOLOGY AND NANOTECHNOLOGY
4.3.3. STABLE VACCINES MAKE IT ATTRACTIVE TO STORE AND TRANSPORT
4.4. CHALLENGES
4.4.1. VACCINES FOR HUMAN USAGE STILL UNDER CLINIC TRAIL PHASE
5. MARKET SEGMENTATION
5.1. MARKET BY TYPE 2017-2025
5.1.1. ANIMAL DNA VACCINE
5.1.2. HUMAN DNA VACCINE
5.2. MARKET BY APPLICATION 2017-2025
5.2.1. HUMAN DISEASE
5.2.2. VETERINARY DISEASE
5.3. MARKET BY TECHNOLOGY 2017-2025
5.3.1. PLASMID DNA VACCINES
5.3.2. PLASMID DNA DELIVERY
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREATS OF SUBSTITUTE PRODUCT
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. KEY BUYING CRITERIA
6.2.1. EFFICACY
6.2.2. COST-EFFECTIVENESS
6.2.3. STABILITY
6.3. KEY MARKET PLAYERS
6.3.1. VICAL INCORPORATED
6.3.2. SANOFI
6.3.3. MERCK AND CORP
6.3.4. GSK
6.4. OPPORTUNITY MATRIX
6.5. VALUE CHAIN ANALYSIS
6.5.1. R&D
6.5.2. MANUFACTURING
6.5.3. RAW MATERIALS
6.5.4. MARKETING, DISTRIBUTION & END USER
6.6. LEGAL, POLICY AND REGULATORY FRAMEWORK
7. GEOGRAPHICAL ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
8. COMPETITIVE LANDSCAPE
8.1. STRATEGIC INITIATIVES
8.1.1. ACQUISITION
8.1.2. PARTNERSHIP
8.1.3. COLLABORATION
8.1.4. INNOVATION
8.1.5. DISINVESTMENT
8.1.6. EXPANSION
9. COMPANY PROFILE
9.1. MARKET SHARE
9.2. ASTELLAS PHARMA INC.
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC INITIATIVE
9.3. DENDREON CORPORATION (ACQUIRED BY SANPOWER GROUP)
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC INITIATIVE
9.4. ELI LILLY AND COMPANY
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC INITIATIVE
9.5. EUROGENTEC S.A
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.5.4. STRATEGIC INITIATIVES
9.6. GLAXOSMITHKLINE INC.
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.6.4. STRATEGIC INITIATIVE
9.7. INOVIO PHARMACEUTICALS, INC.
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. SCOT ANALYSIS
9.7.4. STRATEGIC INITIATIVE
9.8. MADISON VACCINES INCORPORATED (MVI)
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. SCOT ANALYSIS
9.9. MERIAL LIMITED (ACQUIRED BY BOEHRINGER INGELHEIM)
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. SCOT ANALYSIS
9.9.4. STRATEGIC INITIATIVE
9.10. MERCK & CO.
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. SCOT ANALYSIS
9.10.4. STRATEGIC INITIATIVE
9.11. NOVARTIS AG
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. SCOT ANALYSIS
9.11.4. STRATEGIC INITIATIVE
9.12. SANOFI
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. SCOT ANALYSIS
9.12.4. STRATEGIC INITIATIVE
9.13. VGXI
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. SCOT ANALYSIS
9.13.4. STRATEGIC INITIATIVE
9.14. VICAL INCORPORATED
9.14.1. OVERVIEW
9.14.2. PRODUCT PORTFOLIO
9.14.3. SCOT ANALYSIS
9.14.4. STRATEGIC
9.15. XENETIC BIOSCIENCES INC.
9.15.1. OVERVIEW
9.15.2. PRODUCT PORTFOLIO
9.15.3. SCOT ANALYSIS
9.15.4. STRATEGIC INITIATIVE
9.16. ZOETIS INC
9.16.1. OVERVIEW
9.16.2. PRODUCT PORTFOLIO
9.16.3. SCOT ANALYSIS
9.16.4. STRATEGIC INITIATIVE  
TABLE LIST
TABLE 1 NORTH AMERICA DNA VACCINE MARKET 2017-2025 ($ MILLION)
TABLE 2 INTERVENTIONS AND PHASE OF CERTAIN DISEASE/CONDITIONS
TABLE 3 APPROACHES BEING TESTED TO ENHANCE THE LOW IMMUNOGENICITY
TABLE 4 CLINICAL TRIALS OF THE HUMANS INVOLVING DNA VACCINES
TABLE 5 TEMPERATURE REQUIREMENTS IN PRESERVATION FOR VARIOUS VACCINES
TABLE 6 NORTH AMERICA DNA VACCINE MARKET BY TYPE 2017-2025 ($ MILLION)
TABLE 7 NORTH AMERICA ANIMAL DNA VACCINE MARKET 2017-2025($MILLION)
TABLE 8 NORTH AMERICA HUMAN DNA VACCINE MARKET 2017-2025
TABLE 9 NORTH AMERICA DNA VACCINE MARKET BY APPLICATION 2017-2025 ($ MILLION)
TABLE 10 NORTH AMERICA HUMAN DISEASES APPLICATION MARKET 2017-2025 ($MILLION)
TABLE 11 NORTH AMERICA VETERINARY APPLICATION MARKET 2017-2025
TABLE 12 NORTH AMERICA DNA VACCINE MARKET BY TECHNOLOGY 2017-2025 ($ MILLION)
TABLE 13 NORTH AMERICA PLASMID DNA VACCINES TECHNOLOGY MARKET 2017-2025
TABLE 14 NORTH AMERICA PLASMID DNA DELIVERY TECHNOLOGY MARKET 2017-2025
TABLE 15 REGULATIONS TO BE FOLLOWED BEFORE COMMERCIALIZATION

FIGURES LIST
FIGURE 1 NORTH AMERICA DNA VACCINE MARKET 2017-2025 ($ MILLION)
FIGURE 2 NORTH AMERICA DNA VACCINE MARKET 2017-2025 ($ MILLION)
FIGURE 3 NORTH AMERICA DNA VACCINE MARKET IN VETERINARY DISEASES 2017-2025 ($ MILLION)
FIGURE 4 SHARE OF TRIALS BY VACCINE TARGET IN 2016
FIGURE 5 SEGMENT OF CLINICAL TRIALS OF DNA VACCINE BY CANCER MARKERS IN 2016
FIGURE 6 CLINICAL TRIALS OF GENE THERAPY
FIGURE 7 NORTH AMERICA DNA VACCINE MARKET SHARE BY TYPE 2016 & 2025 (%)
FIGURE 8 NORTH AMERICA DNA VACCINES MARKET IN ANIMAL DNA VACCINES 2017-2025 ($ MILLION)
FIGURE 9 NORTH AMERICA DNA VACCINE MARKET IN HUMAN DNA VACCINES 2017-2025($ MILLION)
FIGURE 10 NORTH AMERICA DNA VACCINE MARKET SHARE BY APPLICATION 2016 & 2025 (%)
FIGURE 11 NORTH AMERICA DNA VACCINES MARKET IN HUMAN DISEASES 2017-2025 ($ MILLION)
FIGURE 12 NORTH AMERICA DNA VACCINES MARKET IN VETERINARY APPLICATION 2017-2025 ($ MILLION)
FIGURE 13 NORTH AMERICA DNA VACCINES MARKET IN PLASMID DNA VACCINES TECHNOLOGY 2017-2025 ($ MILLION)
FIGURE 14 NORTH AMERICA DNA VACCINES MARKET IN PLASMID DNA DELIVERY TECHNOLOGY 2017-2025 ($ MILLION)
FIGURE 15 VALUE CHAIN ANALYSIS FOR DNA VACCINE INDUSTRY
FIGURE 16 UNITED STATES DNA VACCINE MARKET 2017-2025 ($ MILLION)
FIGURE 17 CANADA DNA VACCINE MARKET 2017-2025 ($ MILLION)
FIGURE 18 MARKET SHARES OF TOP FIVE COMPANIES FOR DNA VACCINES MARKET IN 2016



★調査レポート[DNAワクチンの北米市場予測] (コード:INKW711106)販売に関する免責事項を必ずご確認ください。
★調査レポート[DNAワクチンの北米市場予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆